Biotech and Pharmaceuticals Medicine

More

  • Sphygmomanometer

    With states squeezing payments to providers even as the economy fuels explosive growth in enrollment, patients are finding it increasingly difficult to locate doctors and dentists who will accept Medicaid coverage. The New York Times reports.

  • FDA

    Of course, I'm off the day all heck breaks loose on the beat and stocks are making big moves all over the place.

  • Cost of healthcare

    President Obama is going all in on the health care plan. He postponed an overseas trip to be on hand for a hoped for vote on the plan this coming Friday.

  • Tomorrow is the day the agency is scheduled to announce if the first once-a-week diabetes treatment, a rejiggered version of the now twice-a-day Byetta, can come to market.

  • X-ray of pelvis showing hip replacement

    A unit of Johnson & Johnson, just months after saying it was phasing out an artificial hip implant because of slowing sales, has warned doctors that the device appears to have a high early failure rate in some patients.

  • trader

    On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.

  • gsk_perfume_ad.jpg

    It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards.

  • This morning, BMO Capital Markets biotech analyst Jason Zhang downgraded shares of Amylin Pharmaceuticals to the equivalent of "Sell."

  • President Barack Obama

    President Obama has high cholesterol. For now, his doctors are prescribing healthy living. But some say he should be put on a statin or cholesterol-lowering drug pronto.

  • Shares of Dendreon fell around 10 percent before the market opened. And now, in regular trading, they're at a new intra-day high. Here's what happened.

  • tv_interview_200.jpg

    When a major pharma company holds analyst/investor meetings as infrequently as Bristol-Myers Squibb, it's kind of a must-cover event.

  • A snowy Capitol Hill in Washington, DC.

    The Food and Drug Administration says its decisions are always based on the science. But on rare occasions ol' mother nature apparently can get in the way.

  • The company logo of GlaxoSmithKline, is seen on the headquarters building in London, Wednesday May 10, 2006. GlaxoSmithKline PLC said Wednesday it has been granted a High Court injunction against animal rights activists who sent threats to the drugmaker's shareholders, barring them from sending more letters or revealing private information about the investors. (AP Photo/Alastair Grant)

    On day five of Avandiagate, GlaxoSmithKline communiques about the brouhaha surrounding the controversial diabetes drug now number six.

  • The company is suing more than half a dozen generic drug firms that want to make a cheaper copy of Crestor years before the patent on the drug is set to expire. But you won't find me sitting in the pews furiously taking notes.

  • I suppose it’s possible President Obama could have come up with a more anti-market reform to deal with its concerns over higher health insurance rates, but short of creating a single-payer health system, creating a seven-member panel to dictate the prices of health insurance is pretty close.

  • Cost of healthcare

    Big pharmaceutical companies have been raising prices on a lot of drugs recently. Some critics say the industry's trying to cash in before government price controls possibly get put into place.

  • Toyota headquarters

    As someone who studies the way people perceive risk, and the importance of trust to those perceptions, it continues to amaze me how many smart successful firms like Toyota manage to forget the importance of trust until they’re in trouble, and then they have to spend huge amounts of money and effort, for years, trying to rebuild it, writes the author David Ropeik.

  • Former U.S. President Bill Clinton seen speaking during the inaugural Rural Summit in Washington, DC

    A source tells CNBC that former President Bill Clinton received two drug-coated stents, called "Xience," made by Abbott Labs.

  • Healthcare coverage and the hastle of forms

    Washington’s new political reality has left the fate of comprehensive healthcare reform uncertain, but there’s still plenty Congress and the Obama administration can do to improve the American healthcare system, writes this CEO.

  • save_money_200.jpg

    Lockstep with Boomer aging, established industries are about to grow exponentially, and new wealth will be created by enterprises yet to be conceived.